Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Express Scripts
AstraZeneca
Moodys
McKesson

Last Updated: January 27, 2023

CLINICAL TRIALS PROFILE FOR ZAFIRLUKAST


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Zafirlukast

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00406861 ↗ Montelukast in ENL Reaction Unknown status The Leprosy Mission Bangladesh N/A 2006-12-01 Objective of the trial is to assess the safety and efficacy of Montelukast in treatment of Erythema Nodosum leprosum (ENL) reaction in multibacillary leprosy patients either in combination with prednisolone or alone. Hypothesis is that montelukast will reduce the severity of ENL reaction in Multibacillary leprosy patients without causing an unacceptably high incidence of adverse effects. Design is a multicentre hospital-based single-blind prospective trial for leprosy patients with ENL reaction. prior written consent will be taken from the patients who will undergo the trial. Endpoints are decrease in severity of ENL and absence of new nerve function impairment
NCT01283061 ↗ Bioequivalence Study of Zafirlukast Tablets 20 mg of Dr. Reddy's Laboratories Limited Under Fasting Condition Completed Dr. Reddy's Laboratories Limited Phase 1 2007-12-01 The objective of this study was to compare the relative bioavailability of zafirlukast tablets 20 mg with that of 'ACCOLATE®' tablets 20 mg (zafirlukast tablets 20 mg) in healthy, adult, human, subjects under fasting conditions and to monitor safety of subjects.
NCT02017197 ↗ Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil Completed Fundação de Amparo à Pesquisa do Estado de São Paulo Phase 4 2014-08-01 The purpose of this study is to assess whether the switch from branded to generic warfarin or between different generic warfarin tablets may cause fluctuation in the results of coagulation tests (International Normalized Rate, acronym INR) in patients, thus predisposing them to unnecessary risks.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Zafirlukast

Condition Name

Condition Name for Zafirlukast
Intervention Trials
Atrial Fibrillation 1
Biological Tumor Markers 1
Breast Cancer 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Zafirlukast
Intervention Trials
Leprosy 1
Erythema Nodosum 1
COVID-19 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Zafirlukast

Trials by Country

Trials by Country for Zafirlukast
Location Trials
United States 2
India 1
Saudi Arabia 1
Bangladesh 1
Brazil 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Zafirlukast
Location Trials
Massachusetts 1
California 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Zafirlukast

Clinical Trial Phase

Clinical Trial Phase for Zafirlukast
Clinical Trial Phase Trials
Phase 4 1
Phase 3 1
Phase 2 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Zafirlukast
Clinical Trial Phase Trials
Completed 2
Recruiting 2
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Zafirlukast

Sponsor Name

Sponsor Name for Zafirlukast
Sponsor Trials
King Abdullah International Medical Research Center 1
The Leprosy Mission Bangladesh 1
Dr. Reddy's Laboratories Limited 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Zafirlukast
Sponsor Trials
Other 6
Industry 1
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
AstraZeneca
McKesson
McKinsey
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.